Original fundamental research starts and ENDS here.
Sectors Tags Blog
ABBV
1 filings
Timeline Columns Start Research 8-K Categories
Showing: Other Clear filter
2025
Q1 1 filings
Jan
Material Impairment Charge
$3.5B non-cash after-tax impairment on emraclidine asset
8-K
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.